Delving into the Latest Updates on NPS-1392 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

NMDA receptor

Mechanism

NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists)

Therapeutic Areas

Nervous System DiseasesCardiovascular Diseases

Active Indication-

Inactive Indication

Stroke

Originator Organization

NPS Pharmaceuticals, Inc.

Active Organization-

Inactive Organization

NPS Pharmaceuticals, Inc.

Drug Highest PhaseDiscontinuedDiscovery

First Approval Date-

Regulation-

The synthesis, biological activity, and single crystal X-ray structure of NPS 1392, (R)-(-)-3,3-bis(3-fluorophenyl)-2-methylpropan-1-amine (3a), a potent, stereoselective antagonist of the NMDA receptor, are described. The NMDA receptor selectively bound the levo isomer (3a) over its enantiomer (3b), which prompted a rigorous absolute configuration assignment. NPS 1392 has the R configuration based on the single-crystal X-ray diffraction analysis of the hydroiodide salt of NPS 1392. This compound is a potential neuroprotective agent for use in the treatment of ischemic stroke.

100 Deals associated with NPS-1392

Login to view more data